ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

  1. Tripathy, D.
  2. Tolaney, S.M.
  3. Seidman, A.D.
  4. Anders, C.K.
  5. Ibrahim, N.
  6. Rugo, H.S.
  7. Twelves, C.
  8. Dieras, V.
  9. Müller, V.
  10. Tagliaferri, M.
  11. Hannah, A.L.
  12. Cortés, J.
Aldizkaria:
Future Oncology

ISSN: 1744-8301,  1479-6694

Argitalpen urtea: 2019

Alea: 15

Zenbakia: 19

Orrialdeak: 2211-2225

Mota: Artikulua

DOI: 10.2217/FON-2019-0180 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus